Skip to main content
Scheduling

Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More

COVID-19 Updates

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, virtual visits and more. Learn More

Jack Meng-Fen Su, MD

Location

Texas Medical Center

Specialty
Cancer and Hematology
Phone: 832-822-4306
Fax: 832-825-1503
Email

msu@bcm.edu

Address

6701 Fannin St., Ste. 1510
Houston, TX 77030

Jack Meng-Fen Su, MD

Associate Professor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine
Hyundai Pediatric Cancer Research Scholar

Education

School Education Degree Year
Baylor College of Medicine Masters Master of Science, Clinical Investigation 2007
Baylor College of Medicine Fellowship Pediatric Oncology Clinical Research 2006
Baylor College of Medicine Fellowship Pediatric Hematology-Oncology 2001
University of California School of Medicine (San Francisco) Residency Pediatrics 1997
University of California, San Francisco Medical School Doctor of Medicine 1990
Stanford University Bachelors Bachelor of Science, Chemistry 1986

About

Dr. Jack Su's clinical interest is in neuro-oncology.

Board Certifications
American Board of Pediatrics
American Board of Pediatrics - Pediatric Hematology-Oncology

Organizations

Organization Name Role
American Association of Cancer Research (AACR) Member
Pediatric Brain Tumor Consortium (PBTC) Member
Society of Neuro-Oncology Member

Research Statement

Dr. Jack Su's research interest is in translational oncology and developing novel agents for treating pediatric CNS tumors. Dr. Su is currently conducting a Children's Oncology Group (COG) phase I study of valproic acid in children with recurrent solid tumors, including brain tumors. He is also developing clinical trials of additional histone deacetylase (HDAC) inhibitors, such as suberoylanilide hydroxamic acid (SAHA), and a poly(ADP-ribose) polymerase (PARP) inhibitor for pediatric CNS tumors.

Dr. Su is conducting pre-clinical studies of HDAC inhibitors, PARP inhibitors, and DNA methylation inhibitors for future clinical trials in pediatric CNS tumors.His research interests are in translational oncology and developing novel agents for treating pediatric CNS tumors.

Language

English, Chinese



* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.